Sangamo Biosciences reported $169.88M in Cash and Equivalent for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acceleron Pharma XLRN:US $ 336.2M 119.31M
Alnylam Pharmaceuticals ALNY:US $ 745.77M 366.22M
Amgen AMGN:US $ 6630M 518M
Avrobio Inc AVRO:US $ 226.44M 6.59M
Bayer BAYN:GR € 3389M 2161M
Biocryst Pharmaceuticals BCRX:US $ 218.43M 8.47M
Biogen BIIB:US $ 1742M 524.5M
Biomarin Pharmaceutical BMRN:US $ 641.53M 25.78M
Bluebird Bio BLUE:US $ 353.47M 86.25M
Gilead Sciences GILD:US $ 7361M 3296M
GlaxoSmithKline GSK:LN 3503M 1254M
Intercept Pharmaceuticals ICPT:US $ 145.62M 52.67M
IONIS PHARMACEUT IONS:US $ 565.12M 150.96M
Karyopharm Therapeutics KPTI:US $ 141.31M 52.84M
Novartis NOVN:VX SF 5117M 1316M
Omeros OMER:US $ 12.7M 3.67M
Regulus Therapeutics RGLS:US $ 41.44M 9.84M
Sangamo Biosciences SGMO:US $ 169.88M 46.9M
Sarepta Therapeutics SRPT:US $ 1697.28M 215.44M
Ultragenyx Pharmaceutical RARE:US $ 290.88M 92.92M
Vertex Pharmaceuticals VRTX:US $ 6063.68M 240.65M
Ziopharm Oncology ZIOP:US $ 76.75M 23.31M